Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
<< vorige   
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
           Alle artikelen van de bijbehorende aflevering
                                       Details van artikel 8 van 8 gevonden artikelen
 
 
  The paroxetine 352 bipolar trial: A study in medical ghostwriting
 
 
Titel: The paroxetine 352 bipolar trial: A study in medical ghostwriting
Auteur: Amsterdam, Jay D.
McHenry, Leemon B.
Verschenen in: International journal of risk & safety in medicine
Paginering: Jaargang 24 (2012) nr. 4 pagina's 221-231
Jaar: 2012-11-07
Inhoud: Background: The problem of ghostwriting in corporate-sponsored clinical trials is of concern to medicine, bioethics, and government agencies. We present a study of the ghostwritten archival report of an industry-sponsored trial comparing antidepressant treatments for bipolar depression: GlaxoSmithKline (GSK) paroxetine study 352. This analysis is based upon publicly available evidence presented in a complaint of research misconduct filed with the Office of Research Integrity of the Department of Health and Human Services. Objectives: We performed a deconstruction of the published study to show how primary and secondary outcome analyses were conflated, turning a ‘negative’ clinical trial into a ‘positive’ study – with conclusions and recommendations that could adversely affect patient health. Methods: The paroxetine 352 study was a randomized, double-blind, placebo-controlled, 19-site trial comparing paroxetine and imipramine in 117 patients with bipolar type I major depressive episode which was unresponsive to prior lithium carbonate therapy. Results: Analysis of the primary outcome measures found no statistically significant difference between paroxetine or imipramine versus placebo. However, the published article concluded that both drugs were efficacious versus placebo for a post hoc subgroup of patients. Conclusions: Few industry-sponsored studies gain public scrutiny. It is important to make these articles transparent to the scientific and medical community.
Uitgever: IOS Press
Bronbestand: Elektronische Wetenschappelijke Tijdschriften
 
 

                             Details van artikel 8 van 8 gevonden artikelen
 
<< vorige   
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland